Literature DB >> 21793702

Estrogen requirements in girls with Turner syndrome; how low is enough for initiating puberty and uterine development?

Na Young Kim1, Dong-Yun Lee, Min Jae Kim, Byung-Koo Yoon, Dooseok Choi.   

Abstract

We conducted this study to find the adequate initial estrogen dose for adolescent girls with Turner Syndrome (TS). We reviewed the medical records of 19 girls with TS and premature ovarian failure (POF), aged 13 to 17 years, who were referred to our adolescent gynecology clinic for ERT. Nine patients were treated with 0.5 mg estradiol valerate (EV) and 10 patients were treated with 1 mg EV as an initial estrogen dose for 1 year. Breast development, changes in uterine size and bone mineral density were measured before and after 1 year of ERT. All patients showed breast budding after 1 year of ERT regardless of estrogen dosage. Uterine development in patients treated with 1 mg EV advanced farther in 1 year of treatment than in patients given 0.5 mg EV. In patients treated with 1 mg EV, uterine length increased by 39.8% and AP fundal diameter by 46%, increments greater than in patients receiving 0.5 mg EV. After 1 year of ERT, bone mineral densities (BMD) increased significantly in both groups, although BMD did not differ significantly between the groups. In conclusion, ERT with 1mg of EV, as a starting dose induced better uterine development than 0.5 mg in prepubertal girls with TS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793702     DOI: 10.3109/09513590.2011.588752

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  1 in total

Review 1.  Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with turner syndrome: a systematic review and meta-analysis.

Authors:  Dahima Cintron; Rene Rodriguez-Gutierrez; Valentina Serrano; Paula Latortue-Albino; Patricia J Erwin; Mohammad Hassan Murad
Journal:  Endocrine       Date:  2016-07-29       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.